Johnson & Johnson Wins FDA Approval for IMAAVY in wAIHA
Spring House, Pennsylvania, U.S. | August 24, 2026 Johnson & Johnson announced that the U.S. Food and Drug Administration...
Johnson & Johnson
Advertisement
Johnson & Johnson Expands TECVAYLI for Multiple Myeloma Care
Beerse, Belgium, August 21, 2026 Johnson & Johnson announced that the European Commission (EC) has approved an indication extension...
Andelyn Biosciences Moves Forward With AAV9-GM2 Gene Therapy
Columbus, Ohio, August 18, 2026 Andelyn Biosciences, Inc., a patient-focused cell and gene therapy contract development and manufacturing organization...
Johnson & Johnson Defines Future of Surgical Intelligence
New Brunswick, New Jersey, August 18, 2026 Johnson & Johnson has published a new Future of Digital Surgery report...
Johnson & Johnson Advances MONARCH QUEST 3 Bronchoscopy
Santa Clara, California, August 17, 2026 Johnson & Johnson announced U.S. 510(k) regulatory clearance for MONARCH™ QUEST 3, the...
Advertisements
Hansoh Pharma’s Ris-Rez Succeeds in Phase 3 Osteosarcoma Trial
SHANGHAI, July 28, 2026 Hansoh Pharmaceutical Group Co., Ltd. announced that risvutatug rezetecan (Ris-Rez/HS-20093), its proprietary B7-H3-directed antibody-drug conjugate...
FibroBiologics Advances CYWC628 Phase 1/2 Wound Trial
HOUSTON, July 31, 2026 FibroBiologics, Inc. has begun dosing patients in its Phase 1/2 clinical trial evaluating CYWC628, a...
Johnson & Johnson Advances RYBREVANT for Head and Neck Cancer
RARITAN, N.J., July 30, 2026 Johnson & Johnson has secured U.S. Food and Drug Administration Priority Review for a...
Contineum Therapeutics Affirms Phase 2 Milestones and Cash Runway
SAN DIEGO, July 30, 2026 Contineum Therapeutics, Inc. reported its second-quarter 2026 financial results while reaffirming key clinical development...
Firefly Bio Acquisition Strengthens J&J Cancer Portfolio
MONTEREY, Calif., July 29, 2026 Johnson & Johnson has completed its $1 billion acquisition of Firefly Bio, Inc., significantly...
Advertisement
